Sign in to view content

Time to Retinal Fluid Control With Faricimab vs Aflibercept in Patients With DME in the Phase 3 YOSEMITE/RHINE Trials

Aleksandra V. Rachitskaya, MD, FASRS

Video
Published 2023

Related

Angiopoietin-2 Signaling and Vascular Stability With Faricimab in Diabetic Macular Edema
Karl G. Csaky, MD, PhD
Annual Meeting Talks
2022
The Evolving Treatment of Proliferative Diabetic Retinopathy: The Diabetic Retinopathy Study to the DRCR Protocol S
Timothy W. Olsen, MD
Webinars and Journal Clubs
2016
Treatment of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy With Intravitreal Aflibercept Injection: 52-Week Results From PANORAMA
W. Lloyd Clark, MD, FASRS
Annual Meeting Talks
2019

Category: Diabetic Retinopathy

See more